… polymyalgia rheumatica (PMR). We therefore aimed to assess the effectiveness and safety of
methotrexate (MTX) and of leflunomide … starting a GCSD, either MTX or LEF, was performed…

… both the efficacy of methotrexate and the incidence of methotrexate-related adverse
events. … and methotrexate can be effective in polymyalgia rheumatica when methotrexate is …

… relapse, MTX dose and reasons for cessation of MTX were collected. The dose of MTX was
… controlled trials for a steroid sparing effect of methotrexate (MTX) in polymyalgia rheumatica …

… Three had failed optimal doses of Methotrexate (as well as IV steroids in the cases of one
of our patients with large vessel GCA). All patients were treated between 3 and 9 months after …

Objectives. Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) affect individuals
older than 50 years of age and corticosteroids are the mainstay of treatment. The aim of our …

… MTX dose in this study was very low (7.5 mg/week orally) [56]. It is possible that higher doses
of MTX … Although these results suggest that leflunomide may be useful in PMR therapy, …

… an important issue and is an unmet need in the treatment of polymyalgia rheumatica (PMR). …
the effectiveness and safety of methotrexate (MTX) and of leflunomide (LEF) in daily clinical …

… There is some evidence for a benefit of methotrexate (MTX) in … with new-onset PMR taking
MTX in addition to a regular GC … In these studies, weekly doses of 7.5–10 mg of MTX were …

… and/or MTX due to flares and/or AEs of prednisolone were identified. The duration of treatment
with LEF and MTX, … Concomitant myalgia and/or polymyalgia rheumatica and large vessel …

… Immunosuppressive agents, such as methotrexate and leflunomide, should be considered
at least at the third relapse. Earlier institution of immunosuppressive therapy may be …